Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for ALTO-300 in Major depressive disorder (MDD). The expected timing is based on the latest available company guidance and may change.
2/12/25- Reported favorable outcome from the planned interim analysis. 5/14/25- Topline results in mid-2026. 5/29/25- Data presented at ASCP'25. 11/12/25:- Enrollment ongoing; Ph2b adjunctive MDD topline data still expected mid-2026. 03/16/26:- ALTO-300 Ph2b adjunctive MDD trial enrollment ongoing; topline data remains expected mid-2026. 05/13/26:- Enhanced eligibility process implemented; ALTO-300 Ph2b MDD topline data timeline shifted to H1 2027. 08/12/26:- Ph2b MDD enrollment remains ongoing. Topline data is expected H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.